01 Heaving Diabetics Population Globally Diabetes and its consequences are expected to register around 4 million deaths in a person aged 20 to 79 in 2020. This equates to one death every eight minutes. Diabetes is responsible for 11.30% of all fatalities among adults in this age range worldwide. According to the AACE (American Association of Clinical Endocrinologists), recent research has found that 22.20% to 26.90% of people hospitalized for the severe condition have diabetes. In hospitalized Coronavirus patients, diabetes and high glucose levels are linked to increased complications, respiratory failure, and fatality.Diabetes is linked to a slew of health problems. When persons with diabetes are compared to people who do not have diabetes, those with diabetes have a 300 percent higher risk of being hospitalized and, as a result, have higher healthcare costs. Because of their young age and longer diabetes duration, children and teenagers are more likely to develop diabetes earlier, lowering their quality of life, shortening their life expectancy, and increasing healthcare expenditures.As a result, diabetes is likely to become more common over time. There is also fear that, as a result of contemporary lifestyle and technology improvements, diabetes may be happening at a higher rate in youth and young adults, increasing the usage of diabetes care devices.
July 9, 2026 – Novo Nordisk launched Awiqli® (insulin icodec), the world's first once-weekly basal insulin, in India for adults with type 1 and type 2 diabetes. The launch reduces insulin injections from 365 to 52 per year and marks India as the seventh global launch market for the therapy.
April 2026 – Dexcom received U.S. FDA clearance for the Dexcom G7 CGM with an extended 15-day sensor wear time for adults with diabetes. The enhanced device provides longer sensor life while maintaining real-time continuous glucose monitoring accuracy.
March 2026 – Tandem Diabetes Care commercially launched Control-IQ+, an advanced hybrid closed-loop insulin delivery algorithm compatible with the t:slim X2™ insulin pump and Tandem Mobi™ System. The technology expands automated insulin delivery support for people with type 1 diabetes (ages 2 years and older) and adults with type 2 diabetes.
January 2026 – Sanofi announced European Commission approval of Teizeild® (teplizumab) for delaying the onset of Stage 3 type 1 diabetes in eligible patients with Stage 2 disease. While a therapeutic product rather than a device, the approval supports broader adoption of advanced diabetes management technologies alongside early intervention strategies.